NASDAQ:HGSI Human Genome Sciences (HGSI) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free HGSI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Human Genome Sciences alerts: Email Address Ad DTIBuy Friday, Sell Monday, No Exceptions Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.And for the first time in 2024, he’s sharing his strategy for free. About Human Genome Sciences Stock (NASDAQ:HGSI)Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company’s products include BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. HGS continues to deliver raxibacumab to the United States Strategic National Stockpile (SNS) for emergency use in treating inhalation anthrax. In addition to the Company’s internal pipeline, it has financial rights to two drugs that GlaxoSmithKline (GSK) has advanced to late-stage development. These include darapladib and albiglutide. A randomized Phase 2 trial is evaluating mapatumumab in combination with Nexavar (sorafenib) for the treatment of advanced hepatocellular cancer. The Company manufactures multiple protein and antibody drugs for use in research, clinical and commercial activities. It produces and purifies these protein and antibody drugs in three process development and manufacturing facilities. In August 2012, GlaxoSmithKline plc acquired HGS.Read More Ad Behind the MarketsThe AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.Here's how you can invest >>> HGSI Stock News HeadlinesFebruary 29, 2024 | msn.comBecoming human: An ancient genome perspectiveFebruary 27, 2024 | msn.comInnovative computational tools provide new insights into the polyploid wheat genomeMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. January 30, 2024 | msn.comThe roles of genes and 3D genome folds in determining healthJanuary 17, 2024 | msn.comUSC Scientists Discover Protein Key to 3D Genome Control and Gene SilencingJanuary 15, 2024 | msn.comNew research reveals major difference in genomes of American and Chinese chestnutDecember 8, 2023 | msn.comGroundbreaking 'Gnocchi' map reveals hidden secrets of the human genomeOctober 19, 2023 | msn.comLabour urged to protect UK’s genetic sciences from hostile foreign statesMarch 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.September 6, 2023 | forbes.comCelera's About-FaceAugust 9, 2023 | msn.comThe Next Human Genome ChallengeJuly 19, 2023 | finanznachrichten.deAutolus Therapeutics plc: Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial OfficerJuly 19, 2023 | stockhouse.comAutolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial OfficerMay 30, 2023 | thestreet.comHuman Genome Hit by Benlysta Sales WorryMay 14, 2023 | msn.comThe Science Of Health: How The New Reference Genome Will Help Understand Link Between Human Genes And HealthMay 11, 2023 | msn.comThe Human Genome: Global DNA data gets diversity bumpMay 11, 2023 | msn.comScientists reveal more inclusive update to human genomeMay 10, 2023 | msn.comScientists have updated the human genome to make it more equitable and inclusiveMay 2, 2023 | washingtonpost.comA genome project cracks mysteries of evolution — and Balto the superdogApril 24, 2023 | msn.comCanadian science pioneers’ role in the Human Genome Project shows why it’s crucial to fund researchApril 13, 2023 | msn.comThe human genome: The most important map ever producedMarch 30, 2023 | msn.comLocal Press: UAE's genome project will benefit the entire Arab worldMarch 8, 2023 | msn.comHuman genome editing offers tantalizing possibilities – but without clear guidelines, many ethical questions still remainMarch 3, 2023 | yahoo.comAsia’s richest man to enter genetic testing market with $145 kitsFebruary 17, 2023 | bbc.co.ukThe human genomeFebruary 16, 2023 | bbc.comWhy the human genome was never completedJanuary 31, 2023 | msn.comHumans are 8% virus – how the ancient viral DNA in your genome plays a role in human disease and developmentSee More Headlines Receive HGSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Human Genome Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:HGSI CUSIPN/A CIK901219 Webwww.hgsi.com Phone+1-301-3098504FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report HGSI Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Human Genome Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Human Genome Sciences investors own include Bank of America (BAC), CEMEX (CX), Cisco Systems (CSCO), Citigroup (C), Beazer Homes USA (BZH), BlackBerry (BB), Advanced Micro Devices (AMD), Alio Gold (ALO), Allot Communications (ALLT) and Altaba (AABA). This page (NASDAQ:HGSI) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThe 3rd Revolution in WarfareWeiss RatingsBill Ackman’s 2024 warningPorter & CompanyUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsYou won't believe what Citigroup just did to it's depositorsAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Human Genome Sciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.